Luo Lianxiang, Qiu Qin, Huang Fangfang, Liu Kaifeng, Lan Yongqi, Li Xiaoling, Huang Yuge, Cui Liao, Luo Hui
Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, 524023, Guangdong, China.
Marine Medical Research Institute of Zhanjiang, Zhanjiang, 524023, Guangdong, China.
J Pharm Anal. 2021 Dec;11(6):683-690. doi: 10.1016/j.jpha.2021.09.001. Epub 2021 Sep 4.
Since December 2019, severe acute respiratory syndrome coronavirus 2 has been found to be the culprit in the coronavirus disease 2019 (COVID-19), causing a global pandemic. Despite the existence of many vaccine programs, the number of confirmed cases and fatalities due to COVID-19 is still increasing. Furthermore, a number of variants have been reported. Because of the absence of approved anti-coronavirus drugs, the treatment and management of COVID-19 has become a global challenge. Under these circumstances, drug repurposing is an effective method to identify candidate drugs with a shorter cycle of clinical trials. Here, we summarize the current status of the application of drug repurposing in COVID-19, including drug repurposing based on virtual computer screening, network pharmacology, and bioactivity, which may be a beneficial COVID-19 treatment.
自2019年12月以来，严重急性呼吸综合征冠状病毒2被发现是2019冠状病毒病（COVID-19）的病原体，引发了全球大流行。尽管存在许多疫苗计划，但COVID-19的确诊病例数和死亡人数仍在增加。此外，还报告了一些变体。由于缺乏经批准的抗冠状病毒药物，COVID-19的治疗和管理已成为一项全球挑战。在这种情况下，药物重新利用是一种有效的方法，可以识别临床试验周期较短的候选药物。在此，我们总结了药物重新利用在COVID-19中的应用现状，包括基于虚拟计算机筛选、网络药理学和生物活性的药物重新利用，这可能是一种有益的COVID-19治疗方法。
